Nebraska's Antrell Taylor wins wrestling national title after losing dad, brother to gun violence
Trump's crypto empire set to expand with new stablecoin and investment fund offerings
Teen recovering after suffering traumatic brain injury at track practice
Police help expecting mother deliver baby on highway
Ukraine railways say Sunday's cyber attack hit its online freight services
Secretive Chinese network tries to lure fired federal workers, research shows
Woman shares 'extremely terrifying' moment she says her car was hit by lightning
Trump has begun another trade war. Here's a timeline of how we got here
Coach breaks world record for run across Iowa
(Reuters) - Medical equipment maker Thermo Fisher Scientific Inc on Wednesday forecast annual profit below Wall Street estimates, as it expects that a slump in demand for its services used to make therapeutics and vaccines to continue this year.
The company forecast an adjusted profit between $20.95 and $22.00 per share for 2024.
Analysts on average were expecting a profit of $22.04 per share in the year, according to LSEG data.
Thermo Fisher and rival Danaher have seen sluggish demand throughout last year for their bioprocessing services used to make therapies and vaccines, as their biotech clients were cautious in their drug development spending owing to rising interest rates.
Slowing growth in China, a key market for both the companies, has also crimped demand for contract research services and lab equipment.
Thermo said it expects revenue of $42.1 billion to $43.3 billion this year, below analysts' expectations of $42.93 billion.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Maju Samuel)
